GSK launches once-daily ReQuip XL in UK
GlaxoSmithKline launched a new treatment for Parkinson's disease in the UK on May 15. ReQuip XL (ropinirole) prolonged-release tablets is the UK's first and only once-daily non-ergot oral dopamine agonist available for the treatment of PD, providing continuous delivery of ropinirole from a single daily dose.
Ropinirole prolonged-release is approved for the treatment of idiopathic PD (monotherapy and adjunct therapy) in patients already taking ropinirole immediate-release tablets and in whom adequate symptomatic control has been established.
Although a number of therapies are available for the treatment of PD, interim results from a recent pan-European survey of 1,026 people conducted by the European Parkinson's Disease Association suggest that there is still a significant unmet need for the treatment of PD.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze